[The stock price of ARS, the first nasal spray approved by the US FDA for allergic reactions, soared by more than 10% in the session] On Friday, the US Food and Drug Administration (FDA) approved the adrenaline nasal spray of ARS Pharmaceuticals, which is also the first needle free adrenaline drug approved for emergency treatment of allergic reactions in the United States. After the news was announced, ARS' stock price surged by over 10% during trading, but then the increase slightly narrowed.